Transcripts Monte Rosa Therapeutics, Inc.

Stocks

Market Closed - Nasdaq 04:00:00 2026-09-04 pm EDT			5-day change	1st Jan Change
13.84 ^USD	-3.76%		+3.44%	-11.73%

Aug. 24	Monte Rosa Therapeutics Doses First Patient in Phase 2 Prostate Cancer Study	MT
Aug. 24	Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer	CI

25-01-14	Monte Rosa Therapeutics, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 05:15 PM
23-10-17	Monte Rosa Therapeutics, Inc. - Special Call

No results match your criteria